Longevity Supplements That Actually Work: A Tiered Evidence Review

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme central to cellular energy production (ATP synthesis) and is a required substrate for sirtuins (SIRT1–SIRT7) and PARP enzymes — the master regulators of DNA repair, mitochondrial biogenesis, and cellular stress response. NAD+ levels decline approximately 50% between ages 40 and 60.

Both NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) serve as NAD+ precursors via the salvage pathway. A landmark 2023 RCT by Okabe et al. in NPJ Aging demonstrated that 250mg/day NMN for 12 weeks in healthy middle-aged adults significantly elevated blood NAD+ levels, improved muscle insulin sensitivity, and increased walking speed in older subjects. A separate 2022 trial by Yi et al. in GeroScience found 300mg/day NR increased NAD+ by 40–90% in 40+ adults with no adverse effects.

The most rigorously studied sports supplement in history — and increasingly recognized as a longevity compound. Creatine phosphate donates phosphate groups to regenerate ATP during high-intensity effort, but its benefits for the 40+ population extend well beyond strength training.

A 2023 meta-analysis in Nutrients covering 22 RCTs found creatine supplementation in adults 50+ significantly reduced muscle loss during periods of inactivity, improved cognitive performance under sleep deprivation, and reduced markers of muscle damage. Critically, a 2021 trial found creatine improved bone density in postmenopausal women when combined with resistance training (p<0.001). The cognitive literature is growing: a 2022 Rae et al. RCT found 5g/day creatine improved working memory and processing speed in vegetarians and omnivores alike, likely via direct creatine phosphorylation in the brain.

EPA and DHA are long-chain polyunsaturated fatty acids with the largest body of human evidence of any longevity supplement category. Their mechanisms span cardiovascular (triglyceride reduction, platelet aggregation inhibition, endothelial function), neurological (DHA as a structural component of neuronal membranes), and anti-inflammatory (EPA → resolvins and protectins).

The 2019 VITAL trial (n=25,871, 5.3 years) found 2g/day omega-3 supplementation reduced major adverse cardiovascular events by 28% in participants not consuming fish. The 2018 REDUCE-IT trial (4g/day icosapentaenoic acid) found a 25% relative risk reduction in MACE in statin-treated patients with elevated triglycerides. Separately, the omega-3 index (EPA+DHA as percentage of red blood cell fatty acids) is independently predictive of all-cause mortality — with a target of ≥8% associated with lowest risk. Most Americans test at 4–5%.

Magnesium is a cofactor in over 300 enzymatic reactions, including ATP production, DNA repair (as a cofactor for DNA polymerase), protein synthesis, and glucose metabolism. It is also a physiological NMDA receptor antagonist and GABA-A activator — making it directly relevant to both sleep quality and stress resilience. An estimated 48–68% of US adults are magnesium-deficient by dietary intake measures, with the gap widening with age due to reduced intestinal absorption and increased urinary excretion.

A large-scale 2023 meta-analysis in BMC Medicine (n=52,000+, 40 prospective cohorts) found higher dietary magnesium intake was associated with significantly lower risk of cardiovascular disease, type 2 diabetes, and all-cause mortality. Supplementation RCTs confirm: 300–500mg/day magnesium reduces fasting glucose, improves insulin sensitivity, lowers blood pressure by 3–5 mmHg, and measurably improves sleep quality (Abbasi et al. 2012 RCT: reduced insomnia severity by 65% vs placebo).

Vitamin D3 (cholecalciferol) functions as a steroid hormone, binding to Vitamin D Receptors (VDRs) in over 37 cell types. It regulates calcium and phosphorus metabolism, immune function (reduces T-regulatory cell dysfunction, suppresses inflammatory cytokines), and modulates over 1,000 genes. Approximately 70% of adults in northern latitudes are deficient (serum 25-OH-D <30 ng/mL), with deficiency strongly correlated with increased all-cause mortality, cancer incidence, and autoimmune disease.

The VITAL trial found 2,000 IU/day D3 reduced cancer mortality by 25% and reduced autoimmune disease risk by 22%. Critically, Vitamin K2 (MK-7 form) is required to activate the osteocalcin and matrix Gla proteins that direct calcium into bone rather than arterial walls — making D3/K2 co-administration essential for cardiovascular safety at higher D3 doses.